Table 1

Immune checkpoint inhibitors under preclinical and clinical development

TargetAgentAntibodyManufacturer
CTLA-4IpilimumabHuman IgG1Bristol-Myers Squibb
PD-1NivolumabHuman IgG4Bristol-Myers Squibb
PembrolizumabHumanised IgG4Merck
MEDI0680HumanisedMedImmune
REGN2810Human IgG4Regeneron/Sanofi
PDR001Humanised IgG4Novartis
BGB-A317HumanisedBeiGene
PidilizumabHumanised IgG1Medivation/CureTech
AMP-224PD-L2 IgG2a fusion proteinGSK
AMP-514PD-L2 fusion proteinGSK
SHR-1210Human IgG4Incyte/Jiangsu
JS001HumanisedShanghai Junshi Biosciences
Tsr-042HumanisedTesaro
PD-L1AtezolizumabHumanised IgG1Genentech/Roche
DurvalumabHuman IgG1MedImmune/AstraZeneca
AvelumabHuman IgG1Merck Serono/Pfizer
BMS-936559Human IgG4Bristol-Myers Squibb
LY3300054Not availableEli Lilly
MEDI4736Humanised IgG1AstraZeneca
KNO35Not available3D Medicines
PD-L2rHIgM12B7Mayo Clinic/NCI
TIM-3Anti-TIM-3 antibody
LAG-3Dual anti-LAG-3/anti-PD-1 antibody
TIGITAnti-TIGIT antibody
BTLAAnti-BTLA antibody
VISTAAnti-VISTA antibody